At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD, PhD, from National Cancer Center Hospital East, Kashiwa, Japan, discusses the progression-free survival and response rates in pre-defined subgroups and biomarker-defined populations in LUX-H&N1, a phase 3 clinical trial comparing second-line afatinib, an ErbB family blocker, with methotrexate for the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma
25th May 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now